Repligen (RGEN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RGEN Repligen

Watchlist

143.100
-2.830-1.94%

Trading Nov 7 15:33 ET

8.01BMarket Cap-4770000P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: Repligen to Report Financial Results Pre-market on November 12
Moomoo NewsNov 6 20:00 ET
Repligen Corporation to Present at Upcoming Investor Conferences
GlobeNewswireNov 5 07:30 ET
Repligen to Report Third Quarter 2024 Financial Results
GlobeNewswireOct 31 07:30 ET
MasterControl Honors Excellence at Annual Masters Summit
PR NewswireOct 29 09:00 ET
J.P. Morgan Maintains Repligen(RGEN.US) With Buy Rating, Cuts Target Price to $190
Moomoo NewsOct 15 08:31 ET · Ratings
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More
Yahoo FinanceOct 14 11:15 ET

Comments

Moomoo AI

Feb 28 11:18

Despite a revenue dip, investors bank on Repligen's future growth, justifying a high P/S ratio. Strong revenue forecasts may keep share prices up, unless analysts' predictions are off.

Repligen Corporation's (NASDAQ:RGEN) Popularity With Investors Is Clear

Moomoo AI

Feb 13 10:54

No recent insider transactions at Repligen isn't concerning, but last year's transactions aren't encouraging. Modest insider ownership suggests alignment with shareholders. However, Repligen has 1 warning sign that shouldn't be ignored.

Repligen Insiders Sold US$1.7m Of Shares Suggesting Hesitancy

Moomoo AI

Dec 19, 2023 08:38

The growth of Repligen parallels investors' sentiment, with EPS growth and yearly share price increases closely matched. Five-year return of 30% suggests consolidation amidst the firm's continued execution of its growth strategy.

Repligen (NASDAQ:RGEN) Jumps 10.0% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns

Moomoo AI

Nov 1, 2023 09:44

Repligen's projected profit growth and evident undervaluation signal a good investment opportunity. The unreflected potential in the share price suggests now is a desirable time to buy.

Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Movers and Shakers

Jul 6, 2023 07:50

Columns Today's Pre-Market Stock Movers And Top Ratings: RGEN, FHN, AFRM, AXP and more

Pre-Market Stock Movers
Gapping up
$Meta Platforms (META.US)$ +0.81% (The social media gianted in premarket trading after the launch of Threads, a direct competitor to Twitter. Meta CEO Mark Zuckerberg said on his Threads account early Thursday that 10 million people had signed up for the platform in seven hours after launching.)
$Sweetgreen (SG.US)$ +5.14% (Sweetgreen jumped more than 4% after Bank of America upgraded...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

RGEN Repligen

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target